Its injectibles range is ramping up fast; so is the cephalosporin range. The company, in last month, has launched generics of Cymbalta (a neurological disorder drug). Analysts at Bank of America-Merrill Lynch expect sales of $40 million and a profit of $25 million from the generic launch during first six months. They raised their earnings estimate for Aurobindo five per cent each for FY14/15, factoring in new launches and market-share ramp-up in existing products. They expect a stronger performance for Aurobindo in the second half of FY14, against the first half and expect the momentum to continue in FY15/16, driven by new launches in injectibles and limited competition in products. Prabhudas Lilladher analyst Pal expects Aurobindo's earnings-per-share to rise 22 per cent in FY15 to Rs 36, a price/earnings ratio of 12.